Pharmaceutical Care Management v. Mylynn Tufte

968 F.3d 901
CourtCourt of Appeals for the Eighth Circuit
DecidedAugust 7, 2020
Docket18-2926
StatusPublished
Cited by1 cases

This text of 968 F.3d 901 (Pharmaceutical Care Management v. Mylynn Tufte) is published on Counsel Stack Legal Research, covering Court of Appeals for the Eighth Circuit primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Pharmaceutical Care Management v. Mylynn Tufte, 968 F.3d 901 (8th Cir. 2020).

Opinion

United States Court of Appeals For the Eighth Circuit ___________________________

No. 18-2926 ___________________________

Pharmaceutical Care Management Association

Plaintiff - Appellant

v.

Mylynn Tufte, in her official capacity as the State Health Officer of North Dakota; Mark J. Hardy, in his official capacity as the Executive Director of the North Dakota Board of Pharmacy; Steven P. Irsfeld, in his official capacity as President of the North Dakota Board of Pharmacy; Wayne Stenehjem, in his official capacity as the Attorney General of North Dakota

Defendants - Appellees ____________

Appeal from United States District Court for the District of North Dakota - Bismarck ____________

Submitted: October 15, 2019 Filed: August 7, 2020 ____________

Before SMITH, Chief Judge, GRUENDER and BENTON, Circuit Judges. ____________

GRUENDER, Circuit Judge.

This case concerns Pharmaceutical Care Management Association’s (“PCMA”) claim that the Employee Retirement Income Security Act of 1974 (“ERISA”), 29 U.S.C. § 1001 et seq., and the Medicare Prescription Drug, Improvement, and Modernization Act of 2003 (“Medicare Part D”), 42 U.S.C. § 1395w-101 et seq., preempt two sections of the North Dakota Century Code (the “legislation”) regulating the relationship between pharmacies, pharmacy benefits managers (“PBMs”), and other third parties that finance personal health services. After PCMA and the State of North Dakota1 cross-moved for summary judgment, the district court determined that only one provision in the legislation was preempted by Medicare Part D and entered judgment in favor of North Dakota on the remainder of PCMA’s claims. We affirm in part, reverse in part, and remand with directions that judgment be entered in favor of PCMA.

PCMA is a national trade association that represents PBMs. PBMs are third- party health plan administrators that manage prescription drug benefits on behalf of health insurance plans. In this role, PBMs negotiate prescription drug prices with drug manufacturers and pharmacies, create networks of pharmacies to fill prescriptions for insured individuals, and process insurance claims when prescriptions are filled.

In 2017, North Dakota passed N.D. Century Code sections 19-02.1-16.1 and 19.02.1-16.2, which, according to North Dakota, “sought to define the rights of pharmacist[s] in relation to [PBMs], and to regulate certain practices by PBMs.” The legislation regulates the fees PBMs and “third-party payer[s]” may charge pharmacies, N.D. Cent. Code § 19-02.1-16.1(2); limits what copayments PBMs or third-party payers may charge, id. § 19-02.1-16.1(4); dictates the quality metrics PBMs and third-party payers may use to evaluate pharmacies and structures how they may reward performance, id. §§ 19-02.1-16.1(3), (11), -16.2(4); prohibits, subject to certain exceptions, PBMs from having “an ownership interest in a patient assistance program and a mail order specialty pharmacy,” id. § 19.02.1-16.2(3);

1 PCMA sued Mylynn Tufte, State Health Officer of North Dakota, Mark Hardy, Executive Director of the North Dakota Board of Pharmacy, Fran Gronberg, President of the North Dakota Board of Pharmacy, and Wayne Stenehjem, Attorney General of North Dakota, in their official capacities. Because of the nature of PCMA’s claims, we refer to the defendants collectively as “North Dakota.”

-2- regulates benefits provisions and plan structures, id. §§ 19-02.1-16.1(3), (4), (5) (8), (9), (11), -16.2(5); and requires certain disclosures on the part of PBMs and prohibits PBMs from setting limits on information pharmacists may provide patients, id. §§ 19-02.1-16.1(6), (7), (10), -16.2(2). A PBM or third-party payer that violates any section of the legislation is guilty of a class B misdemeanor. Id. §§ 19-02.1- 16.1(12), -16.2(6).

Shortly after the legislation’s enactment in 2017, PCMA filed a complaint seeking a declaration of preemption and an injunction prohibiting the enforcement of the legislation. At summary judgment, the district court determined that none of the statutory provisions were preempted by ERISA and that only one of the provisions was preempted by Medicare Part D. PCMA appeals, renewing its argument that both ERISA and Medicare Part D preempt the entire legislation.

We review de novo the district court’s preemption and statutory interpretation rulings. Pharm. Care Mgmt. Ass’n v. Rutledge, 891 F.3d 1109, 1112 (8th Cir. 2018). With certain limited exceptions, ERISA preempts “any and all State laws insofar as they may now or hereafter relate to any employee benefit plan.” 29 U.S.C. § 1144(a) (emphasis added). “The breadth of this section is well known,” Rutledge, 891 F.3d at 1112, and courts have struggled for decades to cabin its reach in order to prevent the clause from becoming “limitless,” Gobeille v. Liberty Mut. Ins., 577 U.S. ---, 136 S. Ct. 936, 943 (2016); N.Y. State Conf. of Blue Cross & Blue Shield Plans v. Travelers Ins., 514 U.S. 645, 655-56 (1995) (rejecting an “uncritical literalism” that extends ERISA’s preemption clause to the “furthest stretch of its indeterminacy”); see also Cal. Div. of Labor Standards Enf’t v. Dillingham Constr., N.A., Inc., 519 U.S. 316, 335 (1997) (Scalia, J., concurring) (counseling courts to avoid reading the clause too broadly because, “as many a curbstone philosopher has observed, everything is related to everything else”).

Endeavoring to clarify ERISA’s “unhelpful text,” Travelers Ins., 514 U.S. at 656, the Supreme Court has determined the clause preempts a state law that “relates to” an ERISA plan by having an impermissible “reference to” or “connection with”

-3- an ERISA plan, id. Here, we need not address the “connection with” element of the analysis because we conclude the legislation is preempted due to its impermissible “reference to” ERISA plans. See Pharm. Care Mgmt. Ass’n v. Gerhart, 852 F.3d 722, 730 (8th Cir. 2017) (“Where a State law is preempted because it has a prohibited ‘reference to’ ERISA or ERISA plans, we need not reach the question of whether it is also preempted under the ‘connection with’ prong of the analysis.”).

A state law has an impermissible “reference to” ERISA plans where it (1) “acts immediately and exclusively upon ERISA plans” or (2) “where the existence of ERISA plans is essential to the law’s operation.” Gobeille, 136 S. Ct. at 943. PCMA asserts that the legislation is preempted because it imposes requirements by reference to ERISA plans through its definitions of “third-party payers” and “plan sponsors.” According to PCMA, these references “ensure[] that the existence of an ERISA plan triggers application” of the legislation’s provisions. The district court disagreed, determining that, because the legislation also covers entities that are not ERISA plans, it neither acts immediately and exclusively upon ERISA plans nor does it make the existence of an ERISA plan essential to the operation of the regulatory scheme.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Pharmaceutical Care Management v. Nizar Wehbi
18 F.4th 956 (Eighth Circuit, 2021)

Cite This Page — Counsel Stack

Bluebook (online)
968 F.3d 901, Counsel Stack Legal Research, https://law.counselstack.com/opinion/pharmaceutical-care-management-v-mylynn-tufte-ca8-2020.